SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.2 CNY | -0.22% |
|
-1.07% | -7.31% |
| Sales 2024 * | 44.43B 6.13B | Sales 2025 * | 50.5B 6.97B | Capitalization | 55.9B 7.71B |
|---|---|---|---|---|---|
| Net income 2024 * | 3.24B 448M | Net income 2025 * | 4.12B 569M | EV / Sales 2024 * | 1.61 x |
| Net Debt 2024 * | 15.46B 2.13B | Net Debt 2025 * | 17.72B 2.45B | EV / Sales 2025 * | 1.46 x |
| P/E ratio 2024 * |
19
x | P/E ratio 2025 * |
14.9
x | Employees | 40,370 |
| Yield 2024 * |
1.62% | Yield 2025 * |
2.08% | Free-Float | 63.46% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -0.22% | ||
| 1 week | -1.07% | ||
| Current month | -1.99% | ||
| 1 month | +0.04% | ||
| 3 months | -4.01% | ||
| 6 months | -17.70% | ||
| Current year | -7.31% |
1 week
22.95
23.63
1 month
22.9524.62
Current year
20.3825.89
1 year
20.3832.08
3 years
20.3891.69
5 years
20.3891.69
10 years
16.5091.69
| Managers | Title | Age | Since |
|---|---|---|---|
De Yong Wen
CEO | Chief Executive Officer | 52 | - |
Dong Ming Li
PSD | President | 55 | 20-10-28 |
Yi Fang Wu
CHM | Chairman | 54 | 04-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Fang Yao
BRD | Director/Board Member | 54 | 10-04-08 |
Qi Yu Chen
BRD | Director/Board Member | 52 | 94-03-31 |
Xiao Hui Guan
BRD | Director/Board Member | 53 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.27% | 2 M€ | -17.92% | - | |
| 1.18% | 4 M€ | -2.96% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-28 | 23.2 | -0.22% | 5,811,447 |
| 24-05-27 | 23.25 | +0.65% | 7,387,616 |
| 24-05-24 | 23.1 | -0.43% | 5,869,037 |
| 24-05-23 | 23.2 | -1.82% | 7,968,148 |
| 24-05-22 | 23.63 | +0.77% | 6,789,958 |
End-of-day quote Shanghai S.E., May 27, 2024
More quotes
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a pharmaceutical group organized around 4 areas of activities:
- research, development and manufacturing of medicines (72.1% of net sales): for the treatment of cardiovascular diseases, digestive tract, metabolism, central nervous system and blood system disorders, and infectious diseases;
- sale of medical equipments and diagnosis products (17.3%);
- medical and hospital services (10.5%);
- other (0.1%).
China accounts for 72.9% of net sales.
Sector
Pharmaceuticals
Calendar
2024-06-26
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
23.2
CNY
Average target price
28.61
CNY
Spread / Average Target
+23.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.31% | 7.72B | |
| +38.59% | 727B | |
| -7.89% | 347B | |
| +15.66% | 319B | |
| +0.24% | 274B | |
| +13.47% | 238B | |
| +7.35% | 204B | |
| -6.42% | 203B | |
| +4.23% | 161B | |
| -1.70% | 160B |
- Stock Market
- Equities
- 600196 Stock
